BMS cuts nivo' trial short, eyes approval pathway

Share this article:
Analysts put weight on BMS in oncology
BMS cuts nivo' trial short, eyes approval pathway

Bristol-Myers Squibb's immuno-oncology portfolio cleared a major hurdle yesterday. The drugmaker cut short a Phase-III trial for anti PD-1 nivolumab after an independent data monitoring committee's analysis showed superior overall survival for the drug, vs. chemo, in patients with advanced untreated melanoma.

Analysts commented that the early stoppage bodes well for other oncology segments the drug is being tested in, such as second-line treatment for non-small cell lung cancer and kidney cancer, and that it could hasten the pathway to approval in the US, despite the fact that the trial used no US study sites, according to clinicaltrials.gov.

Leerink analyst Seamus Fernandez, in an investor note, heralded the news as a “major milestone” for the drug and the immuno-oncology category overall.

In Fernandez's view, there are three major repercussions of the BMS announcement: CheckMate -066 is the first trial to show a survival benefit for any PD-1 antibody; it will likely inform the drugmaker's submission for the EU and Canada—which may confer an edge in those markets against Merck's anti PD-1 pembrolizumab; and its early finish could bode well for the drug's ongoing survival studies in other therapeutic categories.

Another analyst, Credit Suisse's Vamil Divan, wrote that the trial's early conclusion could help the drug's avenue to approval in the US. “[CheckMate -066 is] likely [to] position Bristol-Myers Squibb as the first anti-PD-1 agent approved outside the US, however, we think could FDA could accept [the trial's results] as well.

“We think that the FDA could also initiate a registrational pathway in the US based on this trial, particularly given nivolumab's favorable [Fast Track] status and prior precedent in terms of allowing Merck to register its anti-PD1 pembro based on Phase-I and Phase-II data,” Divan added. Merck's pembro' is expected to be approved in the second half of this year.

That was a point which ISI analyst Mark Schoenebaum also touched on in his note from Tuesday evening: “We believe based on the positive Phase III data reported today the probability of being able to file nivolumab in melanoma by year end 2014 is higher,” than the firm's earlier expectations of 2015.

Divan noted, however, that Merck's pembro' will still likely have a “9-month lead time” in the US. But farther down the line, the analyst foresees BMS “as having the lion's share in advanced melanoma”—owing to its “extremely positive recent data released with the regimen"—and its regimen likely becoming a first-line treatment, whereas Merck's is expected to receive a second-line indication.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...